Overview


According to FutureWise analysis the market for Diphtheria, Pertussis and Tetanus (DTP) Vaccine is expected to reach US$ 8.67 billion by 2031 at a CAGR of 5.30%.

The first immunization given to infants is often the DTaP (Diphtheria, Tetanus, and Acellular Pertussis) vaccine at two months of age. The capital "D" and "P" in DTaP refer to the higher amounts of Diphtheria and Pertussis antigens compared to Tdap products. Three contagious human diseases—diphtheria, tetanus, and pertussis—are prevented by diphtheria, pertussis, and tetanus (DPT) vaccination. To generate acquired immunity against Diphtheria, Pertussis, and Tetanus, these vaccines are administered either during childhood or during middle life. DTP, also known as diphtheria, tetanus, and pertussis, are severe illness brought on by the bacteria. Diphtheria, tetanus, and pertussis vaccines are combined and administered intramuscularly as the DTP vaccine. In order to successfully immunise children up to the age of seven against Diphtheria, Tetanus, and Pertussis (whooping cough), diphtheria and tetanus toxoids and the pertussis vaccine are advised concurrently. This trend has primarily been caused by an increase in demand for combination vaccinations that are tetravalent and then pentavalent. The funding provided by GAVI (Global Alliance for Vaccines and Immunizations) for further DTP-containing vaccines has played a significant role in driving the rising demand for combination products. The pertussis vaccine market is expected to increase rapidly due to the high birth rate and rising demand for the vaccine, which will favorably affect the worldwide Diphtheria, Pertussis, and Tetanus (DTP) Vaccine market. Other factors anticipated to contribute to market expansion include a rise in the frequency of DPT cases, improvements in vaccine administration systems, the creation of technologically sophisticated vaccines, and government initiatives.

FutureWise Market Research has instantiated a report that provides an intricate analysis of Diphtheria, Pertussis and Tetanus (DTP) Vaccine Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the Diphtheria, Pertussis and Tetanus (DTP) Vaccine Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

  • AJ Vaccines
  • Bionet-Asia
  • GlaxoSmithKline plc (GSK)
  • Johnson & Johnson
  • Massbiologics
  • Meiji Holdings Co., Ltd. (KM biologics Co., Ltd.)
  • MerckCo., Inc
  • Panacea Biotec Ltd.
  • Sanofi
  • Serum Institute of India Pvt. Ltd.

(Note: The list of the major players will be updated with the latest market scenario and trends)

By Product Type

  • DTaP Vaccine
  • TD Vaccine
  • Tdap Vaccine

By Age Group

  • Adult
  • Pediatrics

By End User

  • Hospitals
  • Clinics
  • Vaccination Centers

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa


  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants
  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth
  • To provide with an exhaustive analysis on the Diphtheria, Pertussis and Tetanus (DTP) Vaccine Market By Product Type, By Age Group, By End User and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions
  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Diphtheria, Pertussis and Tetanus (DTP) Vaccine Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Diphtheria, Pertussis and Tetanus (DTP) Vaccine Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Diphtheria, Pertussis and Tetanus (DTP) Vaccine Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Diphtheria, Pertussis and Tetanus (DTP) Vaccine Market, By Product Type Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. DTaP Vaccines
        2. TD Vaccines
        3. Tdap Vaccines

  • 8.   Diphtheria, Pertussis and Tetanus (DTP) Vaccine Market, By Age Group Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Adult
        2. Pediatric

  • 9.   Diphtheria, Pertussis and Tetanus (DTP) Vaccine Market, By End User Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Hospitals
        2. Clinics
        3. Vaccination Centers

  • 10.   North America Diphtheria, Pertussis and Tetanus (DTP) Vaccine Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 11.   Latin America Diphtheria, Pertussis and Tetanus (DTP) Vaccine Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 12.   Europe Diphtheria, Pertussis and Tetanus (DTP) Vaccine Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 13.   Asia Pacific Diphtheria, Pertussis and Tetanus (DTP) Vaccine Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 14.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 15.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 16.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. AJ Vaccines
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Bionet-Asia
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. GlaxoSmithKline plc (GSK)
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Johnson & Johnson
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Massbiologics
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Meiji Holdings Co., Ltd. (KM biologics Co., Ltd.)
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. MerckCo., Inc.
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Panacea Biotec Ltd.
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Sanofi
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. Serum Institute of India Pvt. Ltd.
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview

  • 17.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the regulations initiated by healthcare administrations
        5. The overall economic slowdown of the developing and developed nations
  • 18.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients